Skip to main content

TNDM

Stock
Health Care
Medical Devices

Performance overview

TNDM Price
Price Chart

Forward-looking statistics

Beta
1.50
Risk
76.45%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Company info

SectorHealth Care
IndustryMedical Devices
Employees2K
Market cap$3.2B

Fundamentals

Enterprise value$1.4B
Revenue$983.0M
Revenue per employee—
Profit margin-18.71%
Debt to equity320.75

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.79
Dividend per share—
Revenue per share$14.96
Avg trading volume (30 day)$24M
Avg trading volume (10 day)$28M
Put-call ratio—

Macro factor sensitivity

Growth+6.3
Credit-0.7
Liquidity-0.7
Inflation+4.8
Commodities+1.7
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-13.87
Price to sales1.14
P/E Ratio-13.87
Enterprise Value to Revenue1.40
Price to book7.19

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +

Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.

Zacks Investment Research (June 23, 2025)
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.

Benzinga (October 2, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free